We thank Priyank Bhargava and colleagues and Nicholas Brown and colleagues for their interest in TROG 15.03 FASTRACK II trial.1 The main consideration of these correspondences regards the use of thermal ablation, which was not the topic of investigation in the trial. Guidelines from the European Association of Urology2 state that thermal ablation should not be offered routinely to patients with tumours larger than 3 cm and cryotherapy should not be offered for tumours larger than 4 cm (notwithstanding the need for general anaesthetic in a comorbid population with cryotherapy).